Sensei Biotherapeutics (FTH) Expected to Post Earnings on Tuesday

Sensei Biotherapeutics (NASDAQ:FTH) is anticipated to release its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($5.0450) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings data on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. On average, analysts expect Sensei Biotherapeutics to post $-17 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Sensei Biotherapeutics Stock Down 3.4%

FTH traded down $1.00 on Tuesday, hitting $28.24. 91,205 shares of the company’s stock were exchanged, compared to its average volume of 197,006. Sensei Biotherapeutics has a twelve month low of $6.32 and a twelve month high of $37.90. The firm has a market cap of $37.84 million, a price-to-earnings ratio of -0.20 and a beta of -0.26.

Insider Transactions at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was acquired at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the acquisition, the chief executive officer directly owned 764,234 shares of the company’s stock, valued at $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder James Peyer sold 25,000 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the transaction, the insider owned 130,142 shares of the company’s stock, valued at $2,605,442.84. This represents a 16.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders acquired 49,494 shares of company stock valued at $1,188,822. 7.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its stake in Sensei Biotherapeutics, Inc. (NASDAQ:FTH) by 10.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

FTH has been the subject of several recent research reports. Leerink Partners assumed coverage on Sensei Biotherapeutics in a report on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company. Citizens Jmp began coverage on Sensei Biotherapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $51.00 price target on the stock. HC Wainwright started coverage on Sensei Biotherapeutics in a research report on Monday, June 22nd. They set a “buy” rating and a $60.00 price objective for the company. Oppenheimer initiated coverage on Sensei Biotherapeutics in a research report on Tuesday. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Weiss Ratings assumed coverage on Sensei Biotherapeutics in a research note on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $54.75.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.